193 related articles for article (PubMed ID: 32721537)
1. Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.
Afrose SS; Junaid M; Akter Y; Tania M; Zheng M; Khan MA
Drug Discov Today; 2020 Dec; 25(12):2294-2306. PubMed ID: 32721537
[TBL] [Abstract][Full Text] [Related]
2. Biological Role of AKT and Regulation of AKT Signaling Pathway by Thymoquinone: Perspectives in Cancer Therapeutics.
Junaid M; Akter Y; Afrose SS; Tania M; Khan MA
Mini Rev Med Chem; 2021; 21(3):288-301. PubMed ID: 33019927
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. Thymoquinone-based nanotechnology for cancer therapy: promises and challenges.
Ballout F; Habli Z; Rahal ON; Fatfat M; Gali-Muhtasib H
Drug Discov Today; 2018 May; 23(5):1089-1098. PubMed ID: 29374534
[TBL] [Abstract][Full Text] [Related]
5. Protein kinases as therapeutic targets to develop anticancer drugs with natural alkaloids.
Ye H; Wang L; Ma L; Ionov M; Qiao G; Huang J; Cheng L; Zhang Y; Yang X; Cao S; Lin X
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1349-1361. PubMed ID: 34856772
[No Abstract] [Full Text] [Related]
6. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo.
Attoub S; Sperandio O; Raza H; Arafat K; Al-Salam S; Al Sultan MA; Al Safi M; Takahashi T; Adem A
Fundam Clin Pharmacol; 2013 Oct; 27(5):557-69. PubMed ID: 22788741
[TBL] [Abstract][Full Text] [Related]
7. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone.
Kundu J; Chun KS; Aruoma OI; Kundu JK
Mutat Res; 2014 Oct; 768():22-34. PubMed ID: 25847385
[TBL] [Abstract][Full Text] [Related]
9. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
10. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Potential of Thymoquinone: A Novel Bioactive Natural Compound from
Mir PA; Mohi-Ud-Din R; Banday N; Maqbool M; Raza SN; Farooq S; Afzal S; Mir RH
Anticancer Agents Med Chem; 2022; 22(20):3401-3415. PubMed ID: 35546763
[TBL] [Abstract][Full Text] [Related]
12. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase.
Kundu J; Choi BY; Jeong CH; Kundu JK; Chun KS
Oncol Rep; 2014 Aug; 32(2):821-8. PubMed ID: 24890449
[TBL] [Abstract][Full Text] [Related]
14. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
15. Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine.
Zhang Y; Liu M; Wang J; Huang J; Guo M; Zuo L; Xu B; Cao S; Lin X
Curr Drug Targets; 2019; 20(15):1505-1516. PubMed ID: 31376819
[TBL] [Abstract][Full Text] [Related]
16. Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
Rathi AK; Syed R; Singh V; Shin HS; Patel RV
Recent Pat Anticancer Drug Discov; 2017; 12(1):55-72. PubMed ID: 27697069
[TBL] [Abstract][Full Text] [Related]
17. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Brachmann S; Fritsch C; Maira SM; García-Echeverría C
Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
[TBL] [Abstract][Full Text] [Related]
18. Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy.
Mahmoud YK; Abdelrazek HMA
Biomed Pharmacother; 2019 Jul; 115():108783. PubMed ID: 31060003
[TBL] [Abstract][Full Text] [Related]
19. Multi-kinase inhibitors, AURKs and cancer.
Cicenas J; Cicenas E
Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
[TBL] [Abstract][Full Text] [Related]
20. Protein Kinases as Tumor Biomarkers and Therapeutic Targets.
Quan C; Xiao J; Liu L; Duan Q; Yuan P; Zhu F
Curr Pharm Des; 2017 Nov; 23(29):4209-4225. PubMed ID: 28730960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
